IHS Chemical Week

People & Business :: Companies

Biotech: Lonza Ties with Cellectis to Improve Cell Lines

1:22 PM MDT | June 8, 2010 | Alex Scott

Lonza says it has agreed a deal with Cellectis (Paris; France), a biotech firm involved in genome customization, to develop and commercialize bioengineered cell lines for manufacturing biologic drugs.    Under the deal, Cellectis will use meganucleases, which act as molecular scissors to modify Lonza’s cell lines. Meganucleases can be directed to a single, highly specific site in the genome of a cell, thereby allowing a wide range of precise genome modifications, including targeted gene integration, gene knock-out as well as modulation of gene...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa